Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.

BACKGROUND We aimed to assess the kinetics of drug-resistant viral variants (DRVs) harboring the M184V mutation in the proviral DNA of long-term virally suppressed patients, and factors associated with DRV persistence. METHODS HIV-DNA from blood cells stored in 2019 and 2016 was sequenced using both Sanger and ultradeep sequencing (SS and UDS, with a detection threshold of 1%) in ART-treated patients with HIV-RNA <50 copies/mL for at least 5 years, with past M184V mutation documented in HIV-RNA. RESULTS Among the 79 tested patients, by combining SS and UDS, the M184V was found to be absent in 26/79 (33%) patients (M184V- patients), and persisted in 53/79 (67%) (M184V+ patients). The M184V+ patients had a longer history of ART, a lower CD4 nadir and higher pretherapeutic HIV-RNA. Among the 37 patients with viral sequences assessed by UDS, the proportion of M184V+ DRVs significantly decreased between 2016 and 2019 (40% versus 14%, p=0.005). The persistence of M184V was associated with the duration and level of HIV-RNA replication under 3TC/FTC (p=0.0009 and p=0.009, respectively). CONCLUSION While it decreased over time in HIV-DNA, the M184V mutation was more frequently persistent in the HIV-DNA of more experienced patients with longer past replication under 3TC/FTC.

[1]  C. Delaugerre,et al.  Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial). , 2021, The Journal of antimicrobial chemotherapy.

[2]  J. Arribas,et al.  Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. , 2020, The Journal of antimicrobial chemotherapy.

[3]  Hezhao Ji,et al.  Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations , 2020, Viruses.

[4]  R. Siliciano,et al.  Intact proviral DNA levels decline in people with HIV on antiretroviral therapy , 2019 .

[5]  D. Hober,et al.  Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay. , 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  K. Metzner,et al.  Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART , 2019, Nature Communications.

[7]  A. d’Arminio Monforte,et al.  Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients , 2019, Open forum infectious diseases.

[8]  V. Calvez,et al.  Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Harrington,et al.  HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients , 2018, AIDS.

[10]  C. Delaugerre,et al.  Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia , 2018, The Journal of antimicrobial chemotherapy.

[11]  V. Calvez,et al.  Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART , 2018, The Journal of antimicrobial chemotherapy.

[12]  R. Maserati,et al.  Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study , 2018, Open forum infectious diseases.

[13]  Philip L. Tzou,et al.  Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing , 2018, Journal of Clinical Microbiology.

[14]  R. Paredes,et al.  The Role of HIV‐1 Drug‐Resistant Minority Variants in Treatment Failure , 2017, The Journal of infectious diseases.

[15]  M. Peeters,et al.  Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. , 2017, The lancet. HIV.

[16]  C. Katlama,et al.  Individualized antiretroviral therapeutic approaches: less can be more , 2017, AIDS.

[17]  C. Rouzioux,et al.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications , 2016, Clinical Microbiology Reviews.

[18]  R. Dewar,et al.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy , 2016, Proceedings of the National Academy of Sciences.

[19]  R. Siliciano,et al.  Defective proviruses rapidly accumulate during acute HIV-1 infection , 2016, Nature Medicine.

[20]  C. Fagard,et al.  Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. , 2016, The Journal of antimicrobial chemotherapy.

[21]  Trevor Bedford,et al.  Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.

[22]  C. Charpentier,et al.  Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy , 2015, AIDS.

[23]  Jeffrey N. Martin,et al.  HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument , 2015, Antimicrobial Agents and Chemotherapy.

[24]  Ronan Boulmé,et al.  Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure , 2014, AIDS (London).

[25]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[26]  C. Delaugerre,et al.  Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication , 2012, HIV medicine.

[27]  R. Kagan,et al.  A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.

[28]  M. Hughes,et al.  Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine , 2011, Proceedings of the National Academy of Sciences.

[29]  K. Metzner,et al.  Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.

[30]  V. Calvez,et al.  Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. , 2011, The Journal of antimicrobial chemotherapy.

[31]  L. Cuzin,et al.  A large French prospective cohort of HIV‐infected patients: the Nadis Cohort , 2009, HIV medicine.

[32]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[33]  Avettand‐Fènoël Véronique,et al.  LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .

[34]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[35]  Yassine Taoufik,et al.  The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution , 2004, AIDS.

[36]  C. Verhofstede,et al.  Drug-Resistant Variants That Evolve During Nonsuppressive Therapy Persist in HIV-1–Infected Peripheral Blood Mononuclear Cells After Long-Term Highly Active Antiretroviral Therapy , 2004, Journal of acquired immune deficiency syndromes.

[37]  M. Wainberg,et al.  Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 , 2003, Clinical Diagnostic Laboratory Immunology.

[38]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[39]  M. Mouroux,et al.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.

[40]  C. Sabin,et al.  Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. , 2000, The Journal of infectious diseases.

[41]  J. Sninsky,et al.  Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.